Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Defining fallopian tube-derived miRNA cancer signatures.

Dejene SB, Ohman AW, Du W, Randhawa D, Bradley A, Yadav N, Elias KM, Dinulescu DM, Setlur SR.

Cancer Med. 2019 Nov;8(15):6709-6716. doi: 10.1002/cam4.2416. Epub 2019 Sep 10.

2.

A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer.

Hüttenhain R, Choi M, Martin de la Fuente L, Oehl K, Chang CV, Zimmermann AK, Malander S, Olsson H, Surinova S, Clough T, Heinzelmann-Schwarz V, Wild PJ, Dinulescu DM, Niméus E, Vitek O, Aebersold R.

Mol Cell Proteomics. 2019 Sep;18(9):1836-1850. doi: 10.1074/mcp.RA118.001221. Epub 2019 Jul 9.

PMID:
31289117
3.

Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model.

Baldwin P, Ohman AW, Medina JE, McCarthy ET, Dinulescu DM, Sridhar S.

Front Oncol. 2019 May 10;9:353. doi: 10.3389/fonc.2019.00353. eCollection 2019.

4.

Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment.

Baldwin P, Ohman AW, Tangutoori S, Dinulescu DM, Sridhar S.

Int J Nanomedicine. 2018 Nov 29;13:8063-8074. doi: 10.2147/IJN.S186881. eCollection 2018.

5.

Unraveling the Cellular Mechanism of Assembling Cholesterols for Selective Cancer Cell Death.

Wang H, Feng Z, Yang C, Liu J, Medina JE, Aghvami SA, Dinulescu DM, Liu J, Fraden S, Xu B.

Mol Cancer Res. 2019 Apr;17(4):907-917. doi: 10.1158/1541-7786.MCR-18-0931. Epub 2018 Dec 14.

PMID:
30552234
6.

Frontiers in the Pathology and Pathogenesis of Ovarian Cancer: Cancer Precursors and "Precursor Escape".

Soong TR, Dinulescu DM, Xian W, Crum CP.

Hematol Oncol Clin North Am. 2018 Dec;32(6):915-928. doi: 10.1016/j.hoc.2018.07.013. Review.

PMID:
30390765
7.

Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.

Tucker DW, Getchell CR, McCarthy ET, Ohman AW, Sasamoto N, Xu S, Ko JY, Gupta M, Shafrir A, Medina JE, Lee JJ, MacDonald LA, Malik A, Hasselblatt KT, Li W, Zhang H, Kaplan SJ, Murphy GF, Hirsch MS, Liu JF, Matulonis UA, Terry KL, Lian CG, Dinulescu DM.

Clin Cancer Res. 2018 Mar 15;24(6):1389-1401. doi: 10.1158/1078-0432.CCR-17-1958. Epub 2017 Dec 20.

8.

Origin of clear cell carcinoma: nature or nurture?

Kolin DL, Dinulescu DM, Crum CP.

J Pathol. 2018 Feb;244(2):131-134. doi: 10.1002/path.5009. Epub 2018 Jan 2.

PMID:
29178260
9.

Selectively Inducing Cancer Cell Death by Intracellular Enzyme-Instructed Self-Assembly (EISA) of Dipeptide Derivatives.

Li J, Shi J, Medina JE, Zhou J, Du X, Wang H, Yang C, Liu J, Yang Z, Dinulescu DM, Xu B.

Adv Healthc Mater. 2017 Aug;6(15). doi: 10.1002/adhm.201601400. Epub 2017 Feb 24.

10.

Epithelialization of mouse ovarian tumor cells originating in the fallopian tube stroma.

Hua Y, Choi PW, Trachtenberg AJ, Ng AC, Kuo WP, Ng SK, Dinulescu DM, Matzuk MM, Berkowitz RS, Ng SW.

Oncotarget. 2016 Oct 4;7(40):66077-66086. doi: 10.18632/oncotarget.11808.

11.

Enzyme-Instructed Intracellular Molecular Self-Assembly to Boost Activity of Cisplatin against Drug-Resistant Ovarian Cancer Cells.

Li J, Kuang Y, Shi J, Zhou J, Medina JE, Zhou R, Yuan D, Yang C, Wang H, Yang Z, Liu J, Dinulescu DM, Xu B.

Angew Chem Int Ed Engl. 2015 Nov 2;54(45):13307-11. doi: 10.1002/anie.201507157. Epub 2015 Sep 14.

12.

The promise and challenge of ovarian cancer models.

Hasan N, Ohman AW, Dinulescu DM.

Transl Cancer Res. 2015 Feb;4(1):14-28.

13.

Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.

Ohman AW, Hasan N, Dinulescu DM.

Front Oncol. 2014 Nov 18;4:322. doi: 10.3389/fonc.2014.00322. eCollection 2014. Review.

14.

Targeting platinum resistant disease in ovarian cancer.

Morgan SL, Medina JE, Taylor MM, Dinulescu DM.

Curr Med Chem. 2014;21(26):3009-20.

PMID:
24735363
15.

Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.

Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R.

Cancer Cell. 2013 Dec 9;24(6):751-65. doi: 10.1016/j.ccr.2013.10.013.

16.

Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.

Kulkarni AA, Roy B, Rao PS, Wyant GA, Mahmoud A, Ramachandran M, Sengupta P, Goldman A, Kotamraju VR, Basu S, Mashelkar RA, Ruoslahti E, Dinulescu DM, Sengupta S.

Cancer Res. 2013 Dec 1;73(23):6987-97. doi: 10.1158/0008-5472.CAN-12-4477. Epub 2013 Oct 11.

17.

"Take it up a NOTCH": novel strategies for cancer therapy.

Morgan SL, Wyant GA, Dinulescu DM.

Cell Cycle. 2013 Jan 15;12(2):191-2. doi: 10.4161/cc.23375. Epub 2012 Jan 15. No abstract available.

18.

Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.

McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, Chin KT, Partridge JC, Poole BB, Cheng KH, Daggett J Jr, Cullen K, Kantoff E, Hasselbatt K, Berkowitz J, Muto MG, Berkowitz RS, Aster JC, Matulonis UA, Dinulescu DM.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):E2939-48. doi: 10.1073/pnas.1206400109. Epub 2012 Sep 27.

19.

Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity.

Sengupta P, Basu S, Soni S, Pandey A, Roy B, Oh MS, Chin KT, Paraskar AS, Sarangi S, Connor Y, Sabbisetti VS, Kopparam J, Kulkarni A, Muto K, Amarasiriwardena C, Jayawardene I, Lupoli N, Dinulescu DM, Bonventre JV, Mashelkar RA, Sengupta S.

Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11294-9. doi: 10.1073/pnas.1203129109. Epub 2012 Jun 25.

20.

Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.

Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Kelly-Spratt K, Wong CH, Zhang Q, Chin A, Park KS, Goodman G, Gazdar AF, Sage J, Dinulescu DM, Kucherlapati R, Depinho RA, Kemp CJ, Varmus HE, Hanash SM.

Cancer Cell. 2011 Sep 13;20(3):289-99. doi: 10.1016/j.ccr.2011.08.007.

21.

Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy.

Paraskar AS, Soni S, Chin KT, Chaudhuri P, Muto KW, Berkowitz J, Handlogten MW, Alves NJ, Bilgicer B, Dinulescu DM, Mashelkar RA, Sengupta S.

Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12435-40. doi: 10.1073/pnas.1007026107. Epub 2010 Jun 23.

22.

Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.

Pitteri SJ, JeBailey L, Faça VM, Thorpe JD, Silva MA, Ireton RC, Horton MB, Wang H, Pruitt LC, Zhang Q, Cheng KH, Urban N, Hanash SM, Dinulescu DM.

PLoS One. 2009 Nov 19;4(11):e7916. doi: 10.1371/journal.pone.0007916.

23.

Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice.

Romero IL, Gordon IO, Jagadeeswaran S, Mui KL, Lee WS, Dinulescu DM, Krausz TN, Kim HH, Gilliam ML, Lengyel E.

Cancer Prev Res (Phila). 2009 Sep;2(9):792-9. doi: 10.1158/1940-6207.CAPR-08-0236. Epub 2009 Sep 8.

24.

Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer.

Abbott KL, Nairn AV, Hall EM, Horton MB, McDonald JF, Moremen KW, Dinulescu DM, Pierce M.

Proteomics. 2008 Aug;8(16):3210-20. doi: 10.1002/pmic.200800157.

25.

Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2.

Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E, Peter ME.

Cell Cycle. 2007 Nov 1;6(21):2585-90. Epub 2007 Aug 6.

PMID:
17957144
26.

A spatially and temporally restricted mouse model of soft tissue sarcoma.

Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, Young NP, Nielsen GP, Quade BJ, Chaber CJ, Schultz CP, Takeuchi O, Bronson RT, Crowley D, Korsmeyer SJ, Yoon SS, Hornicek FJ, Weissleder R, Jacks T.

Nat Med. 2007 Aug;13(8):992-7. Epub 2007 Aug 5.

PMID:
17676052
27.

Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.

Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17426-31. Epub 2006 Nov 6.

28.

Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.

Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK.

Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9. Epub 2006 Jul 18.

29.

Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer.

Daikoku T, Tranguch S, Trofimova IN, Dinulescu DM, Jacks T, Nikitin AY, Connolly DC, Dey SK.

Cancer Res. 2006 Mar 1;66(5):2527-31.

30.

Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.

Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T.

Nat Med. 2005 Jan;11(1):63-70. Epub 2004 Dec 26.

PMID:
15619626
31.

c-CBL is not required for leukemia induction by Bcr-Abl in mice.

Dinulescu DM, Wood LJ, Shen L, Loriaux M, Corless CL, Gross AW, Ren R, Deininger MW, Druker BJ.

Oncogene. 2003 Dec 4;22(55):8852-60.

PMID:
14654781
32.

Genetic models of obesity and energy balance in the mouse.

Robinson SW, Dinulescu DM, Cone RD.

Annu Rev Genet. 2000;34:687-745. Review.

PMID:
11092843
33.

The central melanocortin system can directly regulate serum insulin levels.

Fan W, Dinulescu DM, Butler AA, Zhou J, Marks DL, Cone RD.

Endocrinology. 2000 Sep;141(9):3072-9.

PMID:
10965876
34.

Agouti and agouti-related protein: analogies and contrasts.

Dinulescu DM, Cone RD.

J Biol Chem. 2000 Mar 10;275(10):6695-8. Review. No abstract available.

35.
36.

Mahogany (mg) stimulates feeding and increases basal metabolic rate independent of its suppression of agouti.

Dinulescu DM, Fan W, Boston BA, McCall K, Lamoreux ML, Moore KJ, Montagno J, Cone RD.

Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12707-12.

Supplemental Content

Loading ...
Support Center